Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 3 Date: 17 Jan 2025
Reviewer's report:
My main concerns have been addressed by the authors and appropriate changes. For me, the
amendments have improved the manuscript but there are still analysis errors.
1. This study mainly explored the clinical value of the systemic immunoinflammatory index
(SII) in predicting recurrence and metastasis in patients with primary liver cancer. Therefore, in
the Kaplan-Meier survival analysis, the SII of optimal cut-off value based on ROC should be
divided into high and low groups, and the recurrence rate and metastasis rate as the endpoint of
the two groups should be compared.
Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 3 Date: 17 Jan 2025
Reviewer's report:
My main concerns have been addressed by the authors and appropriate changes. For me, the
amendments have improved the manuscript but there are still analysis errors.
1. This study mainly explored the clinical value of the systemic immunoinflammatory index
(SII) in predicting recurrence and metastasis in patients with primary liver cancer. Therefore, in
the Kaplan-Meier survival analysis, the SII of optimal cut-off value based on ROC should be
divided into high and low groups, and the recurrence rate and metastasis rate as the endpoint of
the two groups should be compared.
Please review this paper.
user
Title: Clinical value of systemic immunoinflammatory index in predicting recurrence and
metastasis in patients with primary liver cancer
Version: 3 Date: 17 Jan 2025
Reviewer's report:
My main concerns have been addressed by the authors and appropriate changes. For me, the
amendments have improved the manuscript but there are still analysis errors.
1. This study mainly explored the clinical value of the systemic immunoinflammatory index
(SII) in predicting recurrence and metastasis in patients with primary liver cancer. Therefore, in
the Kaplan-Meier survival analysis, the SII of optimal cut-off value based on ROC should be
divided into high and low groups, and the recurrence rate and metastasis rate as the endpoint of
the two groups should be compared.
assistant